Indexat a

Llicència i ús

Citacions

Altmetrics

Impacte en els Objectius de Desenvolupament Sostenible (ODS)

Anàlisi d'autories institucional

Compartir

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Publicat a:Journal Of Clinical Oncology. JCO2400668-JCO2400668 - 2024-09-18 (), DOI: 10.1200/JCO.24.00668

Autors: González-Martín A; Rubio MJ; Heitz F; Depont Christensen R; Colombo N; Van Gorp T; Romeo M; Ray-Coquard I; Gaba L; Leary A; De Sande LM; Lebreton C; Redondo A; Fabbro M; Barretina Ginesta M-P; Follana P; Pérez-Fidalgo JA; Rodrigues M; Santaballa A; Sabatier R; Bermejo-Pérez MJ; Lotz J-P; Pardo B; Marquina G; Sánchez-Lorenzo L; Quindós M; Estévez-García P; Guerra Alía E; Manso L; Casado V; Kommoss S; Tognon G; Henry S; Bruchim I; Oaknin A; Selle F

Afiliacions

Resum

To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer. The multicenter placebo-controlled double-blind randomized phase III ENGOT-OV41/GEICO 69-O/ANITA trial (ClinicalTrials.gov identifier: NCT03598270) enrolled patients with measurable high-grade serous, endometrioid, or undifferentiated recurrent ovarian cancer who had received one or two previous CT lines (most recent including platinum) and had a treatment-free interval since last platinum (TFIp) of >6 months. Patients were stratified by investigator-selected carboplatin doublet, TFIp, BRCA status, and PD-L1 status in de novo biopsy and randomly assigned 1:1 to receive either atezolizumab or placebo throughout standard therapy comprising six cycles of a carboplatin doublet followed (in patients with response/stable disease) by maintenance niraparib until progression. The primary end point was investigator-assessed progression-free survival (PFS) per RECIST v1.1. Between November 2018 and January 2022, 417 patients were randomly assigned (15% BRCA-mutated, 36% PD-L1-positive, 66% TFIp >12 months, 11% previous poly [ADP-ribose] polymerase inhibitor after frontline CT, and 53% previous bevacizumab). Median follow-up was 28.6 months (95% CI, 26.6 to 30.5 months). Atezolizumab did not significantly improve PFS (hazard ratio, 0.89 [95% CI, 0.71 to 1.10]; P = .28). Median PFS was 11.2 months (95% CI, 10.1 to 12.1 months) with atezolizumab versus 10.1 months (95% CI, 9.2 to 11.2 months) with standard therapy. Subgroup analyses generally showed consistent results, including analyses by PD-L1 status. The objective response rate (ORR) was 45% (95% CI, 39 to 52) with atezolizumab and 43% (95% CI, 36 to 49) with standard therapy. The safety profile was as expected from previous experience of these drugs. Combining atezolizumab with CT and maintenance niraparib for late-relapsing recurrent ovarian cancer did not significantly improve PFS or the ORR.

Paraules clau